The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.

All material subject to strictly enforced copyright laws. © 2022 Euromoney, a part of the Euromoney Institutional Investor PLC.

Investors take a big dose of GlaxoSmithKline's offering

GlaxoSmithKline used careful timing to make the most of the dearth of jumbo dollar corporate issues so far this year.


There?s been little jumbo corporate bond issuance for bankers or investors to get their teeth into this year, so GlaxoSmithKline?s $2.5 billion debut dollar offering gave everyone something to celebrate. It was 2004?s second largest corporate dollar bond, after Pacific Gas and Electric?s $6.7 billion offering earlier in March, and the largest dollar deal from a non-US corporate since Telecom Italia last October.

The deal, which comprised a $500 million three-year tranche, a $1.5 billion 10-year and a $500 million 30-year tranche, priced at 40bp, 58bp and 68bp respectively over treasuries. This was even better than the extremely tight price guidance, with a particularly flat curve between 10 and 30 years, and better than GSK could have found in either euros or sterling at the time. At press time, the issue was trading even tighter. ?The three-year is now trading three to four basis points tighter and the 10 and 30 year tranches are 2bp tighter than at launch,? says Morven Jones, managing director at Lehman Brothers.

With the lack of benchmark industrial dollar bond issues in the first quarter, investors lapped up this double-A rated credit.

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.


Unlimited access to and

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually


Unlimited access to and, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors


Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree